- ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2024
- ResMed to Report Third Quarter Fiscal 2024 Earnings on April 25, 2024
- ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis
- Introducing the AirFit F40: Experience Unprecedented Freedom with the Comfort and Optimized Seal Performance of ResMed’s Smallest Full-Face CPAP Mask
- ResMed’s New AirCurve™ 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep Apnea
- ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2024
- ResMed to Report Second Quarter Fiscal 2024 Earnings on January 24, 2024
- ResMed Announces Participation in the 42nd Annual J.P. Morgan Healthcare Conference
- ResMed Notifies Customers About Updated Instructions and Labeling for Masks with Magnets Due to Potential Interference with Certain Medical Devices
- ResMed Secures Significant Victory in Patent Fight Against New York University
More ▼
Key statistics
As of last trade Resmed Inc (RMD:NYQ) traded at 213.18, -12.46% below its 52-week high of 243.52, set on Apr 28, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 203.02 |
---|---|
High | 213.52 |
Low | 201.86 |
Bid | 212.96 |
Offer | 213.34 |
Previous close | 183.42 |
Average volume | 1.27m |
---|---|
Shares outstanding | 147.09m |
Free float | 145.88m |
P/E (TTM) | 30.39 |
Market cap | 26.98bn USD |
EPS (TTM) | 6.04 USD |
Annual div (ADY) | 1.92 USD |
---|---|
Annual div yield (ADY) | 1.05% |
Div ex-date | Feb 07 2024 |
Div pay-date | Mar 14 2024 |
Data delayed at least 15 minutes, as of Apr 26 2024 15:29 BST.
More ▼